Histone Deacetylase Inhibitors Interrupt HSP90•RASGRP1 and HSP90•CRAF Interactions to Upregulate BIM and Circumvent Drug Resistance in Lymphoma Cells

Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here we show that trichostatin A, romidepsin, and panobino...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Leukemia
Hoofdauteurs: Ding, Husheng, Peterson, Kevin L., Correia, Cristina, Koh, Brian, Schneider, Paula A., Nowakowski, Grzegorz S., Kaufmann, Scott H.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5474223/
https://ncbi.nlm.nih.gov/pubmed/27890930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.357
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items